418 related articles for article (PubMed ID: 28317233)
1. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
[TBL] [Abstract][Full Text] [Related]
3. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis.
Loveman E; Copley VR; Scott DA; Colquitt JL; Clegg AJ; O'Reilly KM
BMC Pulm Med; 2015 Apr; 15():37. PubMed ID: 25927225
[TBL] [Abstract][Full Text] [Related]
4. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis.
Dhooria S; Agarwal R; Sehgal IS; Prasad KT; Muth V; Garg M; Bal A; Aggarwal AN; Behera D
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):148-157. PubMed ID: 33093778
[TBL] [Abstract][Full Text] [Related]
5. Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: a real-world evidence study.
Romero Ortiz AD; Jiménez-Rodríguez BM; López-Ramírez C; López-Bauzá Á; Pérez-Morales M; Delgado-Torralbo JA; Villalba Moral C; Alcazar-Navarrete B
BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38663886
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis.
Sugino K; Ono H; Saito M; Ando M; Tsuboi E
PLoS One; 2024; 19(6):e0305429. PubMed ID: 38870246
[TBL] [Abstract][Full Text] [Related]
7. Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Tsurumaki H; Shin Y; Wakamatsu I; Kasahara N; Yamaguchi K; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Respir Investig; 2024 May; 62(3):388-394. PubMed ID: 38460356
[TBL] [Abstract][Full Text] [Related]
8. No drug-drug interactions between selective prolyl-tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants.
Shin W; Park MY; Kim J; Kim J; Nam JH; Choi J; Yang AY; Yoo H; Lee YS; Kim A
Clin Transl Sci; 2024 Jan; 17(1):e13701. PubMed ID: 38105420
[TBL] [Abstract][Full Text] [Related]
9. Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus.
Schreiber J; Schütte W; Koerber W; Seese B; Koschel D; Neuland K; Grohé C
Pneumologie; 2024 Apr; 78(4):236-243. PubMed ID: 38608658
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.
Kreuter M; Bonella F; Wijsenbeek M; Maher TM; Spagnolo P
Biomed Res Int; 2015; 2015():329481. PubMed ID: 26779535
[TBL] [Abstract][Full Text] [Related]
11. Model-based Meta-Analysis on the Efficacy of Pharmacological Treatments for Idiopathic Pulmonary Fibrosis.
Chan P; Bax L; Chen C; Zhang N; Huang SP; Soares H; Rosen G; AbuTarif M
CPT Pharmacometrics Syst Pharmacol; 2017 Oct; 6(10):695-704. PubMed ID: 28699195
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Rangarajan S; Locy ML; Luckhardt TR; Thannickal VJ
Drugs; 2016 Mar; 76(3):291-300. PubMed ID: 26729185
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for dose reduction and discontinuation of nintedanib in fibrotic interstitial lung diseases: Real life data.
Costa E; Pedroso AR; Matos R; Cunha Rodrigues M; Padrão E; Sousa-Neves J; Rolo R
Respir Med; 2024; 225():107603. PubMed ID: 38513874
[TBL] [Abstract][Full Text] [Related]
14. Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients.
Nili M; Epstein AJ; Nunag D; Olson A; Borah BJ
BMC Pulm Med; 2024 Mar; 24(1):141. PubMed ID: 38504247
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system.
Sun X; Wang H; Zhan X; Yan Y; Chen K; An Z; Zhou H
Front Pharmacol; 2024; 15():1256649. PubMed ID: 38860173
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib-associated enterocolitis with intractable diarrhea: a case report.
Miyaguchi K; Tsuzuki Y; Uemuara H; Ishizawa K; Shinomiya S; Matsumoto H; Shiomi R; Ohgo H; Nagata M; Nakamoto H; Imaeda H
Clin J Gastroenterol; 2024 Apr; 17(2):271-275. PubMed ID: 38042763
[TBL] [Abstract][Full Text] [Related]
17. The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks.
Wang HY; Tsai SC; Lin YC; Hou JU; Chao CH
BMC Pulm Med; 2024 Apr; 24(1):160. PubMed ID: 38566026
[TBL] [Abstract][Full Text] [Related]
18. Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.
Saha A; Vaidya PJ; Chavhan VB; Achlerkar A; Leuppi JD; Chhajed PN
Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(1):85-90. PubMed ID: 32476885
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment.
Cojocaru E; Cojocaru T; Pînzariu GM; Vasiliu I; Armașu I; Cojocaru C
J Pers Med; 2023 Dec; 14(1):. PubMed ID: 38248752
[TBL] [Abstract][Full Text] [Related]
20. CYP1A2 Polymorphism and Drug Co-administration Affect the Blood Levels and Adverse Effects of Pirfenidone.
Yang X; Wei J; Yang Y; He Y; Guo L; He X; Zhang L; Chen L
Ther Drug Monit; 2024 May; ():. PubMed ID: 38723157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
